Unveiling 6 Analyst Insights On Kymera Therapeutics
Portfolio Pulse from Benzinga Insights
Six analysts have recently published ratings on Kymera Therapeutics (NASDAQ:KYMR), with a mix of bullish, somewhat bullish, and indifferent sentiments. The average 12-month price target is $44.0, reflecting a 5.19% increase from the previous target. Analysts have adjusted their ratings and price targets, indicating a positive outlook for the company.
August 12, 2024 | 9:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Six analysts have provided mixed ratings on Kymera Therapeutics, with an average 12-month price target of $44.0, indicating a 5.19% increase from the previous target. Analysts have adjusted their ratings and price targets, reflecting a generally positive outlook.
The mixed but generally positive analyst ratings and the increase in the average 12-month price target suggest a favorable short-term outlook for Kymera Therapeutics. The adjustments in ratings and price targets by analysts indicate confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100